Vivani Medical, Inc. reports developments from a clinical-stage biopharmaceutical business focused on miniature, ultra long-acting subdermal drug implant candidates using its proprietary NanoPortal™ technology. News commonly centers on financial results, business updates, manufacturing and clinical-development spending, and progress for semaglutide-based implant candidates such as NPM-139 for chronic weight management and NPM-133 for type 2 diabetes.
The company’s updates also cover Cortigent, its wholly owned subsidiary developing brain implant devices based on precision neurostimulation technology. Cortigent disclosures include the Orion® Visual Cortical Prosthesis System, a cortical stimulation system under development to provide visual perception for blind persons, as well as equity financings, registered direct offerings, private placements, shareholder matters and governance updates.
Vivani Medical (VANI) announced a private placement expected to raise approximately $5.1 million from two members of its board of directors. Chairman Gregg Williams and director Aaron Mendelsohn are purchasing 5,049,506 common shares at $1.01 each under a November 15, 2026 agreement. Gross proceeds exclude estimated offering expenses. Closing is expected on or about November 23, 2026, subject to customary conditions.
Vivani intends to fund research and clinical development of NPM-139, its semaglutide implant, and other candidates, alongside general corporate needs. It expects the proceeds and existing cash resources to fund operations into the third quarter of 2027. The financing follows SLIM-1 Phase 1 results: no NPM-139 participants experienced treatment-related adverse events, and no serious adverse events occurred in the study. Vivani anticipates a Phase 2 dose-ranging weight maintenance trial beginning in 2027.
Vivani Medical (Nasdaq: VANI) reported top-line results from SLIM-1, its completed Phase 1 trial comparing low-dose NPM-139 semaglutide implants with Wegovy injections. The four-week, open-label study enrolled 10 participants per group at one Australian center. No NPM-139 participants had treatment-related adverse events, versus five Wegovy participants, whose events were gastrointestinal. No serious adverse events were reported; implant insertions and removals had no complications.
Weight loss was 0.79% with NPM-139 versus 0.82% with Wegovy. Maximum drug levels after a single administration occurred at approximately 16 days versus approximately 2.4 days, respectively, with no rapid drug-exposure increases for NPM-139. Vivani plans to advance NPM-139 toward a Phase 2 dose-ranging weight-maintenance trial anticipated to begin in 2027, and explore development in patients who have not previously used GLP-1 therapies.
Vivani Medical (Nasdaq: VANI) reported a third-quarter net loss of $7.250 million as it prepared to release SLIM-1 trial results. The loss compared with $6.530 million a year earlier, while loss per share narrowed to $0.08 from $0.11. Cash, cash equivalents and restricted cash totaled $15.5 million at September 30, 2026, versus $20.8 million at June 30.
Vivani expects results later this week from its fully enrolled, 20-participant Phase 1 study of the NPM-139 semaglutide implant. It plans a 2027 investigational new drug application to support a proposed Phase 2 dose-ranging study. A nonexclusive agreement with Novo covers evaluation of NPM-139. The Cortigent-ClearOne merger awaits final regulatory approval and completion of closing and related financing activities; ClearOne aims to raise $10 million to $15 million concurrently with closing.
Vivani Medical (VANI) will participate in two investor conferences in New York on October 14 and 15, 2026. The Maxim Growth Summit takes place October 14 at the Hard Rock Hotel New York; The ThinkEquity Conference follows October 15 at the Mandarin Oriental.
Management will host investor and partner meetings at both conferences. Chief Executive Officer Adam Mendelsohn will present at ThinkEquity. Any webcasts will be available afterward on Vivani’s corporate Investors page.
Vivani Medical (VANI) will participate in two upcoming investor conferences in New York in September 2026.
The company plans to attend the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on September 10, 2026, at the Metropolitan Club, and the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026, at the Lotte New York Palace Hotel.
A pre-recorded company presentation for the H.C. Wainwright conference will be available for online viewing starting at 7 a.m. Eastern Time on September 11, 2026.
Vivani Medical (Nasdaq: VANI) reported second quarter 2026 results and business updates, highlighting completion of enrollment and successful dosing of all 20 participants in SLIM-1™, its first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management. Top-line SLIM-1 data are expected in November 2026, with a Phase 2 dose-ranging trial planned for 2027.
Vivani signed a non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and its NanoPortal™ technology, and its subsidiary Cortigent entered a definitive merger agreement with Nasdaq-listed ClearOne to form Cortigent Holdings, anticipated to trade on Nasdaq under ticker CRGT in the third quarter of 2026. As of June 30, 2026, Vivani reported cash, cash equivalents and restricted cash of $20.8 million, up from $17.6 million at year-end 2025, and a Q2 2026 net loss of $6.4 million, improved from a $7.1 million net loss in Q2 2025.
Vivani Medical (Nasdaq: VANI) announced full enrollment and successful initial dosing of all 20 participants in SLIM-1, a Phase 1, randomized, active-controlled trial of NPM-139, a miniature, subdermal, ultra long-acting semaglutide implant for chronic weight management.
The four-week trial in GLP-1 naïve, overweight or obese participants in Australia compares low-dose NPM-139 in 10 participants with the starting dose of Wegovy (0.25 mg/week semaglutide injection) in 10 participants, focusing on safety, tolerability, pharmacokinetics and measuring weight change. Dosing of the first 10 participants began on July 29, 2026, ahead of schedule, with the remaining 10 dosed one week later; all insertion procedures were completed without issues. Top-line data are expected in November 2026 and may support a planned Phase 2 dose-ranging trial in 2027. Vivani highlights prior NPM-139 preclinical data showing sustainable 20% weight reduction in animal models and a July 2026 collaboration with Novo Nordisk to evaluate NPM-139 and its NanoPortal implant platform, which is designed for six- to twelve-month drug delivery and rapid reversibility of GLP-1 exposure.
Vivani Medical (NASDAQ: VANI) announced it will present at the Emerging Growth Conference on July 15, 2026. CEO Adam Mendelsohn, Ph.D., will provide a company update in an interactive session scheduled for 4:10 p.m. Eastern Time, with live Q&A and an archived webcast available afterward.
Vivani Medical (Nasdaq: VANI) signed a new agreement with Novo Nordisk to allow a non-exclusive internal evaluation of NPM-139, a semaglutide implant using Vivani’s NanoPortal™ technology for chronic weight management.
Vivani also expects to begin a Phase 1 first-in-human study of NPM-139 with Wegovy injections as an active comparator in mid-2026, focused on safety, pharmacokinetics, and tolerability to support a potential Phase 2 dose-ranging trial.
Vivani (Nasdaq: VANI) entered a definitive merger agreement under which its wholly owned subsidiary Cortigent will merge with a ClearOne (Nasdaq: CLRO) subsidiary and become a wholly owned ClearOne unit. Vivani will receive 12,500,000 ClearOne shares and is expected to own 59.4%–67.5% of the combined company.
ClearOne will be renamed Cortigent Holdings, trading on Nasdaq as CRGT. ClearOne plans a concurrent $10–$15 million registered financing. Closing is targeted for Q3 2026, subject to stockholder approvals, financing, minimum net cash, and continued Nasdaq listing.